Table 3.

Outcomes of patients with advanced NSCLC with and without EGFR mutations treated with gefitinib

EGFR mutantWild typeP
Han et al. (17)
    Response (%)6513.7<0.001
    TTP (mo)221.8<0.001
    Median survival (mo)30.56.6<0.001
Mitsudomi et al. (16)
    Response (%)8310<0.0001
    Median survival (mo)>2013.00.0053
Takano et al. (30)
    Response (%)8211<0.0001
    Median survival (mo)20.07.00.0001
Cortes-Funes et al. (38)
    Response (%)6090.001
    Median survival (mo)13.04.90.02
Taron et al. (39)
    Response (%)9413<0.0001
    Median survival (mo)>209.90.001
  • Abbreviation: TTP, time to progression.